机译:一种基于IDH野生型胶质母细胞瘤的基于基因表达的预后签名
Genentech Inc Dept Bioinformat & Computat Biol 1 DNA Way San Francisco CA 94080 USA;
F Hoffmann La Roche Ltd Global Clin Dev Basel Switzerland;
Genentech Inc Oncol Biomarker Dev San Francisco CA 94080 USA;
Mem Sloan Kettering Canc Ctr Dept Neurosurg 1275 York Ave New York NY 10021 USA;
Univ Calif Los Angeles UCLA Dept Neurol Los Angeles CA USA;
ORIC Pharmaceut Inc Dept Translat Med San Francisco CA USA;
Univ Hosp Bonn Dept Neurol Div Clin Neurooncol Bonn Germany;
Mayo Clin Coll Med Dept Lab Med & Pathol Rochester MN USA;
Univ Calif Los Angeles UCLA Dept Neurol Los Angeles CA USA;
Genentech Inc Oncol Biomarker Dev Basel Switzerland;
Univ Hosp Dept Neurol Zurich Switzerland|Univ Zurich Zurich Switzerland;
Heidelberg Univ Dept Neurol Heidelberg Germany|German Canc Res Ctr Heidelberg Germany;
Genentech Inc Dept Bioinformat & Computat Biol 1 DNA Way San Francisco CA 94080 USA;
F Hoffmann La Roche Ltd Global Clin Dev Basel Switzerland;
机译:基于13-基因签名的组合治疗敏感性指数预测IDH野生型和MGMT启动子未甲基化胶质母细胞瘤患者的预后
机译:基于自噬相关基因表达的风险特征在胶质母细胞瘤患者中的预后相关性
机译:验证IDH野生型胶质母细胞瘤9-基因ATE评分的预后值
机译:分泌物囊泡蛋白质组学:胶质母细胞瘤外来和野生型P53基因素质的调节
机译:基于预后和预测基因特征的亚组分析用于早期非小细胞肺癌患者的辅助化疗
机译:自噬相关基因表达为基础的胶质母细胞瘤患者风险签名的预后相关性
机译:初始手术切除和初始诊断发生的长时间是切除复发性IDH野生型胶质母细胞瘤的独立预后因素